Given the potential of emerging advanced therapies, market demand is likely to continue to grow. Generating the required quantity of cells efficiently becomes even more challenging when the cells of interest are attachment-dependent, such as induced pluripotent stem cells (iPSCs). The choice of cell culture platform will have significant operational and commercial impacts.
Download this whitepaper to explore:
- What researchers should consider when creating a risk-mitigating adherent culture process for cell and gene therapy scale-up
- Key factors that should drive your long term scale-up plan
- The operational impacts of platform choice